Share your videos with the world

Sign Up | Log In | Help  

   
 
Related Tags: nutrilite  amway  supplement  recommender  app  vitamin  mineral  dietary  nutrition  health  multivu  61025  project  impact  diabetes  disease  research  apha  pharmacists  health  blood  sugar  patients  multivu  62268  clinical  research  institutes  in  bangalore  acri  clinical  research  center  india  penn  medicine  cancer  research  study  immune  cells  leukemia  patients  cellular  therapy  health  multivu  64691  best  clinical  research  institutes  del  mar  pharmaceutical  glioblastoma  brain  cancer  treatment  tumor  chemotherapy  healthcare  multivu  7037951  euclid  cdi  hospital  clinic  diagnosis  europe  awareness  test  healthcare  multivu  71400524  novoeight  haemophilia  treatment  blood  clot  coagulate  approval  study  healthcare  multivu  71400529  cure  care  medical  journal  perioperative  medicine  neonatal  intensive  healthcare  resource  website  multivu  71400535  st  jude  childrens  research  hospital  ceo  james  r  downing  pediatric  cancer  childhood  diseases  multivu  7256651  best  clinical  research  institutes  in  bangalore  phenogen  sciences  brevagen  brevagenplus  cancer  predictive  risk  assessment  test  women  health  multivu  7337351 
Search // clinical
Results 61-72 of 101 for ' clinical ' (0 seconds)
Jeffrey Bacha, president and CEO of DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) (“DelMar Pharma” or “DelMar”) discusses new clinical research and treatments in development for glioblastoma, the most common and severe form of brain cancer. Less than one out of three patients will survive two years after their diagnosis. DelMar is a cancer-focused company developing new therapies for patients with little to no treatment options. To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7037951-delmar-pharmaceuticals-glioblastoma-brain-tumor-awareness-month
Categories // Science and Technology 
Added: 3857 days ago by MultiVuVideos
Runtime: 6m10s | Views: 1120 | Comments: 1
Not yet rated
 

 

 

The full set of data from EUCLID, the largest ever prevalence study of Clostridium difficile infection (CDI) across Europe, were presented today at the 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Data from 482 European hospitals reveal that in a single day, an average of 109 cases of CDI are missed due to a lack of clinical suspicion or inadequate laboratory testing, potentially leading to more than 39,000 missed cases in Europe each year. To view the Multimedia News Release, go to: http://www.multivu.com/mnr/71400524-EUCLID-clostridium-difficile-infection
Categories // Science and Technology 
Added: 3846 days ago by MultiVuVideos
Runtime: 4m43s | Views: 767 | Comments: 1
Not yet rated
 

 

 

Today, Novo Nordisk announced new phase 3 interim data from its guardianTM2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight® (turoctocog alfa), the first new rFVIII molecule in over a decade, which shows that it provides long-term reduction from bleeding in people with haemophilia A when used as a preventative treatment.1 The results were presented at the World Federation of Haemophilia (WFH) World Congress and support findings from other studies within the guardianTM clinical programme that found NovoEight® demonstrated good efficacy in preventing and treating bleeds without inhibitor development in previously treated patients. To view the Multimedia News Release, go to: http://www.multivu.com/mnr/71400529-novoeight-reduction-of-bleeding-haemophilia-a
Categories // Science and Technology 
Added: 3846 days ago by MultiVuVideos
Runtime: 1m51s | Views: 820 | Comments: 2
Not yet rated
 

 

 

An expert group of specialists have come together to develop three new educational resources: the Journal of Perioperative Medicine, the Journal of Neonatal Intensive Care and an open-access online portal. These resources provide practical advice on key clinical issues, tackle controversial topics on which a consensus is needed, and highlight clinical concerns that need to be addressed in clinical practice. These resources are available through a new educational initiative called Cure&Care and are accessible at: www.cureandcareportal.com. Cure&Care officially launches at Euroanaesthesia 2014, in Stockholm, Sweden, 30 May – 3 June. To view the Multimedia News Release, go to http://www.multivu.com/mnr/71400535-cure-care-new-educational-initiative
Categories // Science and Technology 
Added: 3829 days ago by MultiVuVideos
Runtime: 4m11s | Views: 724 | Comments: 1
Not yet rated
 

 

 

St. Jude Children’s Research Hospital, www.stjude.org, announced today the appointment of James R. Downing, M.D., as its new CEO, effective July 15, 2014. Downing most recently has served as the Deputy Director, Executive Vice President and Scientific Director of the hospital, which is leading the way the world understands, treats and defeats pediatric cancer and other catastrophic diseases. Downing’s primary focus immediately upon assuming the CEO office will be to oversee a new era of clinical, research and infrastructure expansion throughout the St. Jude global network. He succeeds Dr. William E. Evans, who is retiring from the position after 10 years and returning full time to his long-standing pharmacogenomics research program at St. Jude. To view the Multimedia News Release, go to http://www.multivu.com/players/English/7256651-st-jude-children-s-research-hospital-new-era-of-expansion-and-growth/
Categories // News and Politics 
Added: 3801 days ago by MultiVuVideos
Runtime: 2m50s | Views: 1091 | Comments: 1
Not yet rated
 

 

 

Phenogen Sciences, Inc. today announced the availability of BREVAGenplus, an easy-to-use predictive risk test for the millions of women at risk of developing sporadic, or non-hereditary, breast cancer. The test is an enhancement of the company’s first generation product, BREVAGen®. BREVAGenplus assesses both clinical risk factors and genetic markers known to be associated with sporadic, or non-hereditary, breast cancer to determine a woman’s five-year and lifetime risk of developing the disease. The test is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans for Caucasian, Hispanic and African-American women, age 35 years or above, who have not had breast cancer, lobular carcinoma in situ (LCIS) or ductal carcinoma in situ (DCIS), and have one or more risk factors for developing breast cancer. To view the Multimedia News Release, go to http://www.multivu.com/players/English/7337351-phenogen-sciences-introduces-brevagenplus-breast-cancer-risk-assessment-test/
Categories // People and Blog  Business 
Added: 3699 days ago by MultiVuVideos
Runtime: 2m12s | Views: 949 | Comments: 2
Not yet rated
 

 

 

The Crohn’s & Colitis Foundation of America (CCFA) is collaborating with the University of North Carolina School of Medicine (UNC) to create a research partnership between patients with inflammatory bowel disease (IBD) and the scientific community. CCFA Partners is a “patient-powered research network” for Crohn’s disease and ulcerative colitis (collectively known as IBD) that uses state-of-the-art bioinformatics to engage and gather information from patients that researchers can study and analyze along with clinical and other patient-generated data. To view the Multimedia News Release, go to http://www.multivu.com/players/English/7449851-crohn-s-colitis-foundation-ccfa-ibd/
Categories // People and Blog 
Added: 3563 days ago by MultiVuVideos
Runtime: 1m7s | Views: 848 | Comments: 1
Not yet rated
 

 

 

Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies. “We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.” To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
Added: 3548 days ago by MultiVuVideos
Runtime: 4m34s | Views: 862 | Comments: 2
Not yet rated
 

 

 

A recently published scientific study from Lund University by lead researcher Charlotte Erlanson-Albertsson, MD, PhD found that subjects who were trying to lose weight and used the patented spinach extract Appethyl on a daily basis lost 43 percent more weight compared to those ingesting a placebo. In this clinical trial, overweight women were given either a daily five gram dose of Appethyl or a control drink immediately before breakfast. Researchers found that the weight of the women ingesting Appethyl decreased significantly at 43 percent more than subjects ingesting the control drink. This is one of three studies that also compared the effects of Appethyl after 90 days with those found after the first dose and found no decline of effects, indicating that Appethyl takes effect after the first dose and is just as effective after long-term use. One study showed that Appethyl reduced hunger by 25 percent four hours after consumption, in addition to reducing thoughts about food by 33 percent. To view the Multimedia News Release, go to http://www.multivu.com/players/English/7426951-appethyl-spinach-extract/
Categories // Fashion and Lifestyle 
Added: 3495 days ago by MultiVuVideos
Runtime: 1m59s | Views: 760 | Comments: 2
Not yet rated
 

 

 

“Be Youthful: Look Good, Feel Great – and Remain Young at Any Age,” Dr. Shino Bay Aguilera’s most recent publication in English, was just published in Spanish and is available on Amazon.com, through barnesandnoble.com, and electronically for Kindle. In addition, major bookstores in the United States can provide home delivery for individual orders. The book provides insights and tips on the perfect ways to renew and restore your mind, body and, spirit – and describes what it means to actually be “youthful.” Dr. Shino Bay Aguilera is a world-renowned cosmetic and clinical dermatologist and the owner of the Shino Bay Cosmetic Dermatology, Plastic Surgery & Laser Institute. He is known as the #1 injector of Sculptra® in the United States and as the preferred choice of celebrities and public figures. Dr. Aguilera, originally from Panama and a former clothing model, became intrigued by people’s everlasting pursuit of the “fountain of youth” through his consultations. “Be Youthful” explores the many ways to clinically appear youthful, but also details his personal journey about the pursuit of happiness, peace, and self-confidence, which all lead to beauty. To view the Multimedia News Release, go to http://www.multivu.com/players/English/7513051-dr-shino-bay-aguilera-book-be-youthful/
Categories // People and Blog 
Added: 3487 days ago by MultiVuVideos
Runtime: 7m13s | Views: 1000 | Comments: 2
Not yet rated
 

 

 

New data from a school asthma management program, “Building Bridges for Asthma Care,” presented today at the American Thoracic Society 2015 International Conference, show a significant decrease in school absenteeism among children with asthma from inner-city schools who were enrolled in the program. Absences dropped 11.75 percent among children enrolled in Building Bridges, compared to an increase of 8.48 percent in children with asthma not in the program. “Building Bridges for Asthma Care” is a school-based program designed to empower nurses in participating elementary schools to ensure that asthmatic children are identified and provided care according to the National Institute of Health’s clinical treatment guidelines. The objectives of the program are addressing the risk of health disparities and asthma-related absenteeism, as well as its related impact on academic achievement for inner city students. To view the Multimedia News Release, go to http://www.multivu.com/players/English/7506851-gsk-building-bridges-for-asthma-care/
Categories // People and Blog 
Added: 3474 days ago by MultiVuVideos
Runtime: 2m45s | Views: 848 | Comments: 1
Not yet rated
 

 

 

Evidence from the Childhood Cancer Survivor Study suggests that changes in childhood cancer treatment have reduced deaths from the late effects of cancer treatment and extended the lives of childhood cancer survivors. St. Jude Children’s Research Hospital investigators led the research, which will be presented today at the plenary session of the 2015 annual meeting of the American Society of Clinical Oncology (ASCO). The study is one of four being featured at the plenary session press briefing, which highlights research that ASCO deems as having the highest scientific merit and greatest potential to affect patient care. To view the Multimedia News Release, go to http://www.multivu.com/players/English/7532851-st-jude-cancer-research/
Categories // People and Blog 
Added: 3461 days ago by MultiVuVideos
Runtime: 3m25s | Views: 813 | Comments: 1
Not yet rated
 

 

 

Page 6 of 9  |  Go to page     |  ««FIRST «Previous  Next» LAST»»



About Us   |   Help  |   Advertise on ClipMoon   |   Terms of Use   |   Privacy Policy   |   Copyright   |   Contact   |   Link us   |   RSS 
Copyright © 2007-2024 ClipMoon.com. All rights reserved.